Tyra Biosciences to Participate at Upcoming Investor Conferences
- CARLSBAD, Calif. , May 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences: Bank of America Global Healthcare Conference, May 13-15, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Tuesday, May 13, 2025, at 5:15 PM PT Location: Las Vegas, NV Jefferies Global Healthcare Conference, June 3-5, 2025 Format: One-on-one investor meetings Location: New York, NY UBS Biotech 1x1 Symposium, June 24, 2025 Format: One-on-one investor meetings Location: New York, NY A live and archived webcast of the fireside chat will be available via the For Investors page on the Investor section of the TYRA website.
- 05/12/2025
|
Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights
- - BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment - - Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC) - - Cash, cash equivalents, and marketable securities of $318.9 million at Q1 2025; runway through at least 2027 - CARLSBAD, Calif. , May 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress.
- 05/08/2025
|
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
- - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC), BEACH301 for pediatric achondroplasia (ACH) and SURF301 for metastatic urothelial cancer (mUC) - - Cash, cash equivalents, and marketable securities of $341.4 million at YE 2024; runway through at least 2027 - CARLSBAD, Calif. , March 27, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted recent corporate progress.
- 03/27/2025
|
Tyra Biosciences to Present at Upcoming Investor Conferences
- CARLSBAD, Calif. , Feb. 11, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 11-12, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Wednesday, February 12, 2025, at 2:00 PM ET Location: Virtual TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Monday, March 3, 2025, at 9:50 AM ET Location: Boston Jefferies Biotech on the Beach Summit, March 11-12, 2025 Format: One-on-one investor meetings Location: Miami Barclays 27th Annual Global Healthcare Conference, March 11-13, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Wednesday, March 12, 2025, at 8:30 AM ET Location: Miami A live and archived webcast of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.
- 02/11/2025
|
Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
- CARLSBAD, Calif. , Jan. 22, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts were accepted for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), taking place January 23-25, 2025, in San Francisco, CA.
- 01/22/2025
|
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
- -TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2 2025- CARLSBAD, Calif.
- 01/10/2025
|
Post-Election Insider Buying in These 6 Stocks Is Huge
- 24/7 Wall St. Insights As we race toward the end of the year, the past week brought some huge insider share purchases.
- 11/17/2024
|
Tyra Biosciences to Present at Upcoming Investor Conferences
- CARLSBAD, Calif. , Nov. 13, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Jefferies London Healthcare Conference, November 19-21st, 2024: Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, November 19th, at 2:00 pm GMT.
- 11/13/2024
|
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
- - Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - - Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif. , Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30, 2024, and highlighted recent corporate progress.
- 11/07/2024
|
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
- – TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies – – First child with achondroplasia expected to be dosed in Q1 2025 – CARLSBAD, Calif. , Oct. 28, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 for children with achondroplasia (BEACH301).
- 10/28/2024
|
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?
- On Thursday, Tyra Biosciences, Inc. TYRA released clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial (mUC) cancer from its ongoing SURF301 Phase 1/2 study.
- 10/25/2024
|
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
- - Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity - - Positive safety results across all QD doses, with infrequent FGFR2/FGFR1-associated toxicities - - Conference call scheduled for October 25th, 2024, at 8AM EDT - CARLSBAD, Calif. , Oct. 24, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial (mUC) cancer from its ongoing SURF301 Phase 1/2 study.
- 10/24/2024
|
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
- CARLSBAD, Calif. , Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC).
- 10/23/2024
|
Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point
- Tyra Biosciences will release interim data for its FGFR3-inhibitor TYRA-300 in treating urothelial carcinoma and solid tumors at ENA 2024 on October 25th. Positive interim data could advance TYRA-300 towards a phase 2 study for metastatic urothelial carcinoma and non-muscle invasive bladder cancer patients. TYRA-300 also shows potential for treating skeletal dysplasia disorders, with an IND filing for achondroplasia expected in the second half of 2024.
- 10/21/2024
|
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
- BofA Securities has upgraded Tyra Biosciences TYRA, a clinical-stage biotechnology company focused on developing next-generation precision medicines.
- 10/18/2024
|
Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)
- -TYRA will also present two posters on PK/PD of TYRA-300 and a Trials-in-Progress from SURF301 - CARLSBAD, Calif. , Oct. 11, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the selection of three abstracts for presentation, including a late-breaking oral presentation, at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024), taking place October 23-25, 2024, in Barcelona, Spain.
- 10/11/2024
|
The Schall Law Firm Is Looking Into Tyra Biosciences Inc For Possibly Violating Securities Laws And The Firm Seeks Shareholder Participation
- LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/12/2024
|
Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference
- CARLSBAD, Calif. , Sept. 11, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today its participation at the 2024 Cantor Global Healthcare Conference.
- 09/11/2024
|
Tyra Biosciences, Inc. May Have Defrauded Shareholders And Impacted Individuals Are Invited To Join The Schall Law Firm's Investigation
- LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/11/2024
|
Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer
- -Dr. Warner brings over twenty years of proven clinical development leadership to TYRA having successfully led global development and secured approvals for medicines across oncology and skeletal disease- CARLSBAD, Calif. , Sept. 10, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Doug Warner, M.D.
- 09/10/2024
|
The Schall Law Firm Has Launched An Inquiry Into Tyra Biosciences Inc For Securities Law Violations And Investors Are Urged To Contribute
- LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/10/2024
|
Tyra Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Wants Shareholders To Participate
- LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/09/2024
|
Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet
- The consensus price target hints at a 27.9% upside potential for Tyra Biosciences (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 09/09/2024
|
Fraudulent Practices May Have Been Committed By Tyra Biosciences Inc And Affected Investors Are Urged To Reach Out To The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/07/2024
|
Investors Are Invited By The Schall Law Firm To Partake In An Inquiry In Tyra Biosciences, Inc's Possible Violations Of Securities Regulations
- LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/06/2024
|
Tyra Biosciences, Inc. Is Being Looked Into For Acting Wrongfully And The Schall Law Firm Has Launched An Investigation That Shareholders Can Join
- LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/05/2024
|
The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Possible Securities Related Infractions And Stockholders Can Assist
- LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/04/2024
|
Tyra Biosciences Inc Stockholders Can Partake In An Inquiry Into Whether The Company Defrauded The Public
- LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/02/2024
|
Attention Investors: The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Potentially Violating Securities Laws And Investors Can Reach Out
- LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/01/2024
|
An Inquiry Is Being Made Into Whether Tyra Biosciences Has Defrauded The Public And The Schall Law Firm Wants Shareholders To Help
- LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/31/2024
|
Tyra Biosciences May Have Broken Securities Laws And Impacted Stakeholders Are Urged To Lend A Hand To The Schall Law Firm's Inquiry
- LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/30/2024
|
The Public Is Encouraged To Reach Out To The Schall Law Firm About An Inquiry Into Tyra Biosciences Inc.'s Potentially Fraudulent Actions
- LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/29/2024
|
The Schall Law Firm Invites Investors In Tyra Biosciences Inc To Partake In An Investigation Into Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/28/2024
|
An Inquiry Has Been Opened Into Tyra Biosciences Inc's Possible Securities Related Impropriety And Impacted Stakeholders Should Join
- LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/27/2024
|
TYRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Shareholders to Contact the Firm Today!
- NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TYRA.
- 08/27/2024
|
Tyra Biosciences Inc Is Being Investigated For Possible Securities Law Violations And The Schall Law Firm Seeks Shareholder Involvement
- LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/26/2024
|
TYRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm Today!
- NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TYRA.
- 08/26/2024
|
The Schall Law Firm Is Inquiring Into Tyra Biosciences Inc.'s Potential Securities Fraud And Affected Investors Can Participate
- LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/25/2024
|
TYRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm Today!
- NEW YORK, NY / ACCESSWIRE / August 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TYRA.
- 08/25/2024
|
Tyra Biosciences Inc. Shareholders Can Reach Out To The Schall Law Firm About An Investigation Into Possible Breaches Of Securities Laws
- LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/24/2024
|
Investors With Losses In Tyra Biosciences Inc. Are Urged To Join An Inquiry Into Possible Securities Fraud With The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/23/2024
|
TYRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm Today!
- NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TYRA.
- 08/23/2024
|
TYRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Stockholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TYRA.
- 08/22/2024
|
Tyra Biosciences Inc. Shareholders Encouraged To Participate In Securities Fraud Investigation With The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/21/2024
|
The Schall Law Firm Invites TYRA Stakeholders To Be A Part Of A Securities Fraud Investigation Into Tyra Biosciences, Inc.
- LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/21/2024
|
TYRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Stockholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TYRA.
- 08/21/2024
|
TYRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Shareholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TYRA.
- 08/20/2024
|
TYRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Shareholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TYRA.
- 08/19/2024
|
TYRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Shareholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TYRA.
- 08/18/2024
|
TYRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TYRA.
- 08/16/2024
|
TYRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TYRA.
- 08/15/2024
|
TYRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TYRA.
- 08/14/2024
|
Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights
- - SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Reported preclinical proof-of-concept with TYRA-300 in HCH, demonstrating increases in long bone length and binding against the HCH altered protein - - IND cleared for TYRA-430, an FGFR4/3 biased inhibitor for HCC - - Announced Chief Medical Officer transition plan; search for an external candidate underway with guidance from Science & Technology (S&T) Committee of the Board, including recent additions Dr. Susan Moran and Dr. S. Michael Rothenberg - - Cash, cash equivalents, and marketable securities of $373.8 million at Q2 2024 - CARLSBAD, Calif.
- 08/07/2024
|
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)
- - In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein - -TYRA remains on track to submit ACH Investigational New Drug Application (IND) in 2H24- CARLSBAD, Calif. , July 2, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced preclinical proof-of-concept results with TYRA-300, an investigational oral FGFR3 selective inhibitor, in hypochondroplasia (HCH).
- 07/02/2024
|
Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock?
- Tyra Biosciences (TYRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 06/07/2024
|
Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?
- The consensus price target hints at a 27.3% upside potential for Tyra Biosciences (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 06/07/2024
|
Tyra Biosciences to Present at Upcoming Investor Conferences
- CARLSBAD, Calif. , May 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, May 28-29, 2024 : Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, May 28, 2024, at 1:00 pm ET.
- 05/23/2024
|
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
- - TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Cash, cash equivalents, and marketable securities of $382.5 million at Q1 2024 - - Susan Moran, M.D., M.S.C.E. and S.
- 05/09/2024
|
Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S.
- CARLSBAD, Calif. , May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced changes to its Board of Directors with the appointments of Susan Moran, M.D.
- 05/07/2024
|
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
- - Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 - - TYRA-300 Phase 2 ACH IND submission on track for 2H 2024 - - Initiated SURF201 Phase 1 study and dosed first patient with TYRA-200 - - Strengthened balance sheet with approximately $200 million PIPE in Q1 2024; pro-forma cash, cash equivalents, and marketable securities of approximately $403.5 million - CARLSBAD, Calif. , March 19, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent corporate progress.
- 03/19/2024
|
Tyra Biosciences to Present at Upcoming Investor Conferences
- CARLSBAD, Calif. , Feb. 27, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: TD Cowen's 44th Annual Healthcare Conference, March 4-6th : Todd Harris, CEO of TYRA, will present a company overview on Wednesday, March 6, 2024, at 2:10 pm ET.
- 02/27/2024
|
Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
- CARLSBAD, Calif. , Feb. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that Todd Harris, CEO of TYRA, will present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 2pm ET.
- 02/07/2024
|
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
- CARLSBAD, Calif. , Feb. 2, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the PIPE) for gross proceeds of approximately $200 million.
- 02/02/2024
|
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
- CARLSBAD, Calif. , Feb. 1, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to TYRA-300, an oral FGFR3 selective inhibitor, for the treatment of achondroplasia.
- 02/01/2024
|
Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300
- - Initiated SURF201 Phase 1 Study; dosed first patient with TYRA-200- - Cleared multiple dose cohorts in SURF301 and continues to dose escalate with TYRA-300- - Received FDA feedback on TYRA-300 Phase 2 ACH study: IND submission planned for 2H 2024- CARLSBAD, Calif. , Dec. 22, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it has initiated the SURF201 Phase 1 study of TYRA-200 and provided positive updates on its oral FGFR3-selective inhibitor, TYRA-300.
- 12/22/2023
|
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
- - Enrollment and dose escalation ongoing in SURF301 Phase 1/2 oncology - - Presented additional preclinical data on TYRA-300 in achondroplasia at ASBMR and ASHG - - First patient to be dosed in TYRA-200 Phase 1 by YE 2023 - - Strong cash position of $215.7 million as of Q3 2023 - CARLSBAD, Calif. , Nov. 7, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30, 2023 and highlighted recent corporate progress.
- 11/07/2023
|
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings
- CARLSBAD, Calif. , Sept. 21, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that TYRA will deliver oral presentations on TYRA-300 for achondroplasia at the American Society for Bone and Mineral Research (ASBMR) and the American Society of Human Genetics (ASHG) 2023 annual meetings.
- 09/21/2023
|
Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference
- CARLSBAD, Calif. , Sept. 12, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate at the 2023 Cantor Global Healthcare Conference, taking place September 26-28, 2023, in New York, NY.
- 09/12/2023
|
Tyra Biosciences: FDA ODD Designation Progresses TYRA-300
- Tyra's net loss continues to improve in Q2 2023. TYRA-300 has been granted Orphan Drug Designation status by the FDA recently, continuing its progression to market. Tyra's substantial cash reserves and ongoing trials support the development of its pipeline for at least the next 2 years to come.
- 08/29/2023
|
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights
- -Orphan Drug Designation granted to TYRA-300 for achondroplasia- - SURF301 Phase 1/2 oncology study remains on target; enrollment ongoing in Part B - -TYRA-200 Phase 1 study on track; first patient to be dosed in 2H 2023- - Strong cash position of $232.4 million as of Q2 2023- CARLSBAD, Calif. , Aug. 10, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended June 30, 2023 and highlighted recent corporate progress.
- 08/10/2023
|
Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia
- CARLSBAD, Calif. , Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead precision medicine program, TYRA-300, for the treatment of achondroplasia.
- 08/01/2023
|
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet
- The consensus price target hints at a 52.2% upside potential for Tyra Biosciences, Inc. (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 06/07/2023
|
Tyra Biosciences: Early Stage Developer Of Novel FGFR3-Selective Molecules
- TYRA has the first FGFR3 inhibitor in the clinic. The company has a large market cap for an early-stage company and a good deal of cash. They do not have clinical data yet.
- 06/01/2023
|
Tyra Biosciences to Participate in Upcoming Investor Conferences
- CARLSBAD, Calif. , May 25, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences: TD Cowen's 4th Annual Oncology Innovation Summit: Todd Harris, CEO of TYRA, will participate in a virtual fireside chat on Tuesday, May 30th, 11:00 am – 11:25 am ET.
- 05/25/2023
|
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'
- Tyra Biosciences, Inc. (TYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
- 05/23/2023
|
Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)
- Tyra Biosciences, Inc. (TYRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 03/27/2023
|
Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings?
- Tyra Biosciences (TYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/01/2023
|
Tyra Biosciences to Present at Upcoming Investor Conferences
- CARLSBAD, Calif. , Nov. 10, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences in November: H.C.
- 11/10/2022
|
Tyra Biosciences to Participate at September 2022 Investor Conferences
- CARLSBAD, Calif. , Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences: H.C.
- 09/08/2022
|
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress
- CARLSBAD, Calif. , Sept. 5, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the Company will be presenting preclinical data on TYRA-300 during a poster session at the European Society for Medical Oncology (ESMO) 2022 Congress, being held in person September 9-13, 2022 in Paris, France.
- 09/05/2022
|
4 Health Care Stocks For Your November 2021 Watchlist
- Could these health care stocks be buys on President Biden's latest vaccine mandate?
- 11/04/2021
|
